Moleculin Biotech, Inc. filed an 8-K on November 18, 2026, disclosing that South Korea's Ministry of Intellectual Property issued a decision to grant a patent covering the company's method of reconstituting liposomal Annamycin.
Key Highlights
- Patent granted: South Korea's Ministry of Intellectual Property issued a decision to grant a patent titled "Method of Reconstituting Liposomal Annamycin" to Moleculin Biotech.
- Application number: The Korean patent application is No. 10-2022-7000486, according to the filing.
- Compound covered: The patent relates to liposomal Annamycin, also identified in the filing as naxtarubicin.
- IP estate scope: The filing states the company's international intellectual property estate protects Annamycin across three complementary technology areas and more than 20 jurisdictions in North America, Europe, Asia-Pacific, and other key regions.
- New market added: According to the filing, the allowance "adds another major market to Moleculin's international intellectual property estate."
South Korea Patent Decision Expands Moleculin's Annamycin IP Coverage
Moleculin Biotech, Inc. (NASDAQ:MBRX) disclosed via a Regulation FD filing on November 18, 2026 that South Korea's Ministry of Intellectual Property has issued a decision to grant a patent covering its method of reconstituting liposomal Annamycin, the drug also referred to in the filing as naxtarubicin. The Korean patent application assigned number 10-2022-7000486 carries the title "Method of Reconstituting Liposomal Annamycin."
According to the filing, the company's international intellectual property estate already spans more than 20 jurisdictions across North America, Europe, Asia-Pacific, and other key regions, and protects Annamycin across three complementary technology areas. The company disclosed that the South Korean grant decision "adds another major market" to that estate.
The disclosure was made through a press release attached as Exhibit 99.1 and incorporated by reference into the 8-K. The filing notes that the information furnished under Item 7.01, including the press release, "shall not be 'filed' for the purpose of the Securities Exchange Act of 1934" and is not automatically incorporated by reference into other filings unless specifically identified as such. The report was signed by Jonathan P. Foster on behalf of the registrant.
What Was Disclosed
Moleculin Biotech filed an 8-K disclosing that South Korea's Ministry of Intellectual Property has decided to grant a patent on Korean application No. 10-2022-7000486, covering the company's method of reconstituting liposomal Annamycin, expanding its international IP portfolio to more than 20 jurisdictions.




Please wait processing your request...